Sertraline oral concentrate
US7067555B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 3, 2004 |
| Grant date | Jun 27, 2006 |
| Priority date | — |
| Expiry date | Mar 4, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.